(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION
`
`TREATY (PCT)
`
`(19) World Intellectual Property Organization
`International Bureau
`
`22 October 2009 (22.10.2009)
`
`(43) International Publication Date
`
`(10) International Publication Number
`WO 2009/129365 Al
`
`
`(51)
`
`International Patent Classification:
`AOIN 43/36 (2006.01)
`A61K 31/40 (2006.01)
`
`(21)
`
`International Application Number:
`
`PCT/US2009/040754
`
`(22)
`
`International Filing Date:
`
`(25)
`
`(26)
`
`(30)
`
`(71)
`
`(72)
`(75)
`
`Filing Language:
`
`Publication Language:
`
`16 April 2009 (16.04.2009)
`
`English
`
`English
`
`Priority Data:
`61/046047
`
`18 April 2008 (18.04.2008)
`
`US
`
`Applicant (for all designated States except US): GLAXO
`GROUP LIMITED [GB/GB]; Glaxo Wellcome House,
`berkeley avenue, Greenford, Middlesex UB6 ONN (GB).
`
`Inventors; and
`Inventors/Applicants (for US only): LAINE, Dramane
`Ibrahim [FR/US]; 709 Swedeland Road, King of Prussia,
`PA 19406 (US). LIN, Guoliang [CN/US]; 709 Swede-
`land Road, King Of Prussia, PA 19406 (US). MCCLE-
`LAND, Brent, W. [US/US]; 709 Swedeland Road, King
`Of Prussia, PA 19406 (US). PALOVICH, Michael, R.
`[US/US]; 709 Swedeland Road, King of Prussia, PA
`19406 (US).
`
`(74)
`
`Agents: KANAGY, James, M. et al; GlaxoSmithKline,
`Corporate Intellectual Property, UW2220, 709 Swedeland
`Road, P.O. Box 1539, King of Prussia, PA 19406-0939
`(US).
`
`(81) Designated States (unless otherwise indicated, for every
`kind gf national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
`CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ,
`EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
`HR, HU,ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
`KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
`MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
`NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
`SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA,
`UG, US, UZ, VC, VN, ZA, ZM, ZW.
`
`(84) Designated States (unless otherwise indicated, for every
`kind d regional protection available): ARIPO (BW, GH,
`GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 7M,
`ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
`TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
`ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
`MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR),
`OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
`MR, NE, SN, TD, TG).
`Declarations under Rule 4.17:
`
`as to applicant's entitlement
`apatent
`(Rule 4.1 7(H))
`
`to apply for and be granted
`
`to claim the priority of
`as to the applicant's entitlement
`the earlier application (Rule 4.1 7(Hi))
`
`go inventorship (Rule 4.1 7(iv))
`Published:
`
`with international search report (Art. 21(3))
`
`(54) Title: CATITEPSIN C INHIBITORS
`
`—=2
`
`(1)
`
`(Ry),
`
`(57) Abstract: This invention relates to compounds of formula (J which are useful for treating chronic obstructive disease, and
`the like.
`
`
`
`wo2009/129365A1IMITINMINIIMTNAIATITIRAAITAAA
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`Cathepsin C Inhibitors
`
`CROSS REFERENCE TO PRIOR APPLICATIONS
`
`This application claims the benefit to US provisional 61/046047 filed 18 April
`
`2008.
`
`FIELD OF THE INVENTION
`
`This invention relates to certain ]-cyano-3-pyrrolidinyl-N-substituedsulfonamides
`
`that are cathepsin C inhibitors, and their use in the treatment of diseases mediated by the
`
`10
`
`cathepsin C enzyme such as chronic obstructive pulmonary disease.
`
`BACKGROUND OF THE INVENTION
`
`Cathepsins are a family of enzymes included in the papain superfamily of cysteine
`
`proteases. Cathepsins B,C, F,H,K,L,8S, V, and X have been described in the scientific
`
`15
`
`literature. Cathepsin C is also known in the literature as Dipeptidyl Peptidase I or "DPPI."
`
`A number of recently published studies have begun to describe the role cathepsin C
`
`plays in certain inflammatory processes. See E.g. Adkison et al., The Journal dg Clinical
`
`Investigation 109:363-371 (2002); Tran et al., Archives d Biochemistry and Biophysics
`
`403:160-170 (2002); Thiele et al., The Journal fo Immunology 158: 5200-5210 (1997);
`
`20
`
`Bidere et al., The Journal d Biological Chemistry 277: 32339-32347 (2002); Mabeeetal.,
`
`The Journal dg Immunology 160: 5880-5885; McGuire et al., The Journal o Biological
`
`Chemistry, 268: 2458-2467; and Paris et al., FEBS Letters 369: 326-330 (1995). From
`
`these studies, it appears that cathepsin C is co-expressed with certain serine proteases,
`
`which are released from inflammatory cells recruited to cites of inflammation, and acts as
`
`25
`
`a physiological activator of these proteases. Once activated, these proteases are capable of
`
`degrading various extracellular matrix components, which can lead to tissue damage and
`
`chronic inflammation.
`
`For example, Chronic Obstructive Pulmonary Disease ("COPD") is a chronic
`
`inflammatory disease where cathepsin C appears to play arole. The American Thoracic
`
`30
`
`Society defines COPD as "a disease characterized by the presence of airflow obstruction
`
`due to chronic bronchitis or emphysema; the airflow obstruction is generally progressive,
`
`may be accompanied by airway hyperreactivity, and may be partially reversible."
`
`American Journal fo Respiratory and Critical Care Medicine 152: S$77-S120 (1995).
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`Chronic bronchitis is generally characterized by a chronic productive cough, whereas
`
`emphysemais generally characterized by permanent enlargement of the airspaces distal to
`
`the terminal bronchioles and airway wall destruction. Chronic bronchitis and cmphyscma
`
`usually occur together in COPDpatients.
`
`Cigarette smoking is a significant risk factor for developing COPD. Exposure to
`
`cigarette smoke and other noxious particles and gases may result in chornic inflammation
`
`of the lung.
`
`In response to such exposure, inflammatory cells such as CD8-+ Tcells,
`
`macrophages, and neutrophils are recruited to the area. These recruited inflammatory cells
`
`release proteases, which are believed to play a major role in the disease etiology by
`
`10
`
`degrading airway walls. Proteases believed to be involved in this process include the
`
`scrinc protcascs ncutrophil clastasc ("NE"), chymase ("CY"), cathcpsin G, protcinase 3
`
`and granzymes A and B. Cathepsin C appearsto be involved in activating these enzymes.
`
`Rheumatoid arthritis ("RA") is another chronic inflammatory disease where
`
`cathepsin C appears to play arole. Neutrophils are recruited to the site ofjoint
`
`15
`
`inflammation and release cathepsin G, NE, and proteinase 3, which are believd to be
`
`responsible for cartilage destruction associated with RA. Cathepsin C appears to be
`
`involved in activating these enzymes.
`
`Other conditions where cathepsin C may play arole include osteoarthritis, asthma,
`
`and Multiple Sclerosis. See E.g. Matsui K. Yuyama N.Akaiwa M. Yoshida NL. Maeda
`
`20
`
`M. Sugita Y. Izuhara K., Identification of an alternative splicing variant of cathepsin
`
`C/dipeptidyl-peptidase LL. Gene. 293(1-2): 1-7, 2002 Jun 26; Wolters PJ. Laig- Webster M.
`
`Caughey GH., Dipeptidyl peptidase I cleaves matrix-associated proteins and is expressed
`
`mainly by mast cells in normal dog airways, American Journal of Respiratory Cell &
`
`Molecular Biology. 22(2): 183-90, 2000.
`
`25
`
`One approachto treating these conditions is to inhibit the activity of the serine
`
`proteases involved in the inflammatory process, especially NE activity. See E.g.,
`
`Ohbayashi, "Neutrophil elastase inhibitors as treatment for COPD", Expert Opin. Investig.
`
`Drugs 11(7): 965-980 (2002); Shapiro, "Neutrophil Elastase: Path Clearer, Pathogen
`
`Killer, or Just Pathologic?", Am. J. Respir. Cell Mol. Biol. 26: 266-268 (2002).
`
`In light of
`
`30
`
`the role cathepsin C plays in activating certain serine proteases, especially NE,it is
`
`desirable to prepare compoundsthat inhibit its activity, which thereby inhibit serine
`
`protease activity. Thus, there is a need to identify compounds that inhibit cathepsin C,
`
`which can be used in the treatment of a variety of conditions mediated by cathepsin C.
`
`2
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`SUMMARY OF THE INVENTION
`
`In a first instance this invention relates to compounds of formula (1)
`
`or a salt thereof wherein
`
`R, is Ci-C ,alkyl; or aryl or arylCi-C ,alkyl where aryl is unsubstituted or
`
`substituted by halo, Ci-C ,alkyl, halo-substituted-Ci-C ¢alkyl, Ci-C alkoxy optionally
`substituted with halo, or S(O), where y is 0-2;
`nis 1-5,
`
`10
`
`each Riis independently halo; OR2; Ci-Cioalkyl unsubstituted or substituted by
`
`halo; CN; C(O)NR 3R,; NO,; NHC(O)NR 5R,; NR{Rg; a heteraromatic ring containing 1-3
`
`heteroatoms selected from the group consisting of N, O or S; aryl, unsubstituted or
`
`substituted by halo or Ci-C¢ alkyl; C3-Cecycloalkyl; C4-Cecycloalkenyl
`
`;Ci-Cioalkenyl; C,-
`
`15
`
`Cioalkynyl; or C(O)OR ,;
`
`R, is H, Cci-C 6 alkyl, haloCi-C 6 alkyl, C(O)Ro;
`
`R3 is H; Ci-C, alkyl; C,-C,cycloalkyl,; or C,-C,heterocycloalkyl containing N, O or
`
`S and where when the ring heteroatom is N it is optionally substituted by CN;
`
`R, is H, or Ci-C, alkyl;
`
`20
`
`Rs and R, are independently H; Ci-C, alkyl; aryl unsubstituted or substituted by
`
`halo, Ci-C ,alkoxy, Ci-C ,alkyl, or OR,; Ci-Ci , alkyl unsbustituted or substituted by halo or
`
`Ci-C ,alkoxy;, C,-C,cycloalkyl; C,-C,cycloalkylalkyl; Ci-Cioalkenyl; Ci-Cioalkynyl; C,-
`
`C,heteroycloalkyl; C,-C,heteroycloalkyl Ci-C alkyl, heteroarylCi-C alkyl or heteroaryl
`
`wherein the heteroaryl ring is unstubstituted or substituted by halo, Ci-C,¢ alkyl or halo-
`
`25
`
`substituted-Ci-C , alkyl; or arylCi-C ,alkyl wherein the aryl group is unsubstituted or
`
`substituted by halo, OR,, or C(O);
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`R, and R gare independently H; Ci-Cioalkyl; arylCi-C¢alkyl wherein the aryl group
`
`is unsubstituted or substituted by R9, halo, or Ci-Cealkyl; Ci-Cioalkyl substituted by C,-
`
`Cecycloalkyl, onc or more OH groups, halo; hetcroarylCi-C ¢alkyl; or hetcroaryl; or
`
`Rg is OH, Ci-C¢ alkyoxy or NR2R3., wherein R,, or R, are independently H or Ci-
`
`Cealkyl.
`
`In a second instance, this invention relates to the use of a compound of formula (1)
`
`or a pharmaceutically acceptable salt thereof in the prevention, management or treatment
`
`of arespiratory or inflammatory disease, such as chronic obstructive pulmonary disease or
`
`rhinitis.
`
`10
`
`In a further aspect, this invention relates to apharmaceutically acceptable
`
`formulation comprising a compound of formula (D or a pharmaceutically acceptable salt
`
`thercof and a pharmaccutically acceptable cxcipicnt.
`
`15
`
`Terms and Definitions
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`For the avoidance of doubt, unless otherwise indicated, the term "substituted"
`
`means substituted by one or more defined groups.
`
`In the case where groups may be
`
`selected from a numberofalternative groups the selected groups may be the same or
`
`different.
`
`20
`
`The term "independently" means that where more than one substituent is selected
`
`from a number ofpossible substituents, those substituents may be the same or different.
`
`For the avoidance of doubt, unless otherwise indicated, the term "substituted" means
`
`substituted by one or more defined groups.
`
`In the case where groups may be selected from
`
`anumber of alternative groups the selected groups may be the same or different.
`
`25
`
`The term "independently" means that where more than one substituent is selected
`
`from a number of possible substituents, those substituents may be the same or different.
`
`An "effective amount” means that amount of a drug or pharmaceutical agent that
`
`will elicit the biological or medical response of a tissue, system, animal or humanthat is
`
`being sought, for instance, by aresearcher or clinician. Furthermore, the term
`
`30
`
`"therapeutically effective amount" means any amount which, as compared to a
`
`corresponding subject who has not received such amount, results in improved treatment,
`
`healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`the rate of advancement of a disease or disorder. The term also includes within its scope
`
`amounts effective to enhance normal physiological
`
`function.
`
`As.used herein the term "alkyl" refers to a saturated straight- or branched-chain
`
`hydrocarbon radical having the specified number of carbon atoms. As used herein,
`
`the
`
`terms "Ci-Cg alkyl" and "Ci_Cio alkyl" refers to such a group having at least
`
`1 and up to 6
`
`or 10 carbon atoms respectively. Examples of such branched or straight-chained alkyl
`
`groups useful in the present invention include, but are not limited to, methyl, ethyl, n-
`
`propyl,
`
`isopropyl,
`
`isobutyl, n-butyl,
`
`t-butyl, n-pentyl,
`
`isopentyl, n-hexyl, n-heptyl, n-octyl,
`
`n-nonyl, and n-decyl, and branched analogs of the latter 5 normal alkanes.
`
`10
`
`The term "Ci-Cio-alkenyl" refers to straight or branched hydrocarbon chains
`
`containing the specified number of carbon atoms andat Icast 1, or morc, carbon-carbon
`
`double bonds. Examples include ethenyl (or ethenylene) and propenyl (or propenylene).
`
`When the term "Ci-Cioalkynyl" (or "alkynylene")
`
`is used it refers to straight or
`
`branched hydrocarbon chains containing the specified number of carbon atoms and at least
`
`15
`
`1, or more, carbon-carbon triple bonds. Examples include ethynyl (or ethynylene) and
`
`propynyl
`
`(or propynylene).
`
`When "Cs-C5Cycloalkyl" is used it refers to a non-aromatic,
`
`saturated, cyclic
`
`hydrocarbon ring containing the specified number of carbon atoms. So, for example,
`
`the
`
`term "C3_Cs cycloalkyl" refers to anon-aromatic cyclic hydrocarbon ring having from
`
`20
`
`three to eight carbon atoms. Exemplary "C3-C6 cycloalkyl" groups useful in the present
`
`invention include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
`
`cycloheptyl and cyclooctyl.
`
`The term "C4-C6cycloalkenyl” refers to a non-aromatic monocyclic carboxycyclic
`
`ring having the specified number of carbon atoms and up to 3 carbon-carbon double bonds.
`
`25
`
`"Cycloalkenyl"
`
`includes by way of example cyclopentenyl and cyclohexenyl.
`
`"Halo" means the halogen radical fluoro, chloro, bromo, or iodo.
`
`"Haloalkyl" means a Ci-Cioalkyl, Ci-Cio-alkenyl, or Ci-Cioalkynyl group that is
`
`substituted with one or more halo substituents. Haloalkyl
`
`includes trifluoromethyl.
`
`Where "C.-C; heterocycloalkyl"
`
`is used, it means a non-aromatic heterocyclic ring
`
`30
`
`containing the specified number of ring atoms being, saturated or having one or more
`
`degrees of unsaturation and containing one or more heteroatom substitutions selected from
`
`O,S and/or N. Such aring may be optionally fused to one or more other "heterocyclic"
`
`ring(s) or cycloalkyl ring(s). Examples of “heterocyclic” moieties include, but are not
`
`5
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`limited to, aziridine, thiirane, oxirane, azetidine, oxetane, thietane, tetrahydrofuran, pyran,
`
`1,4-dioxane, 1,3-dioxane, piperidine, piperazine, 2,4-piperazinedione, pyrrolidine,
`
`imidazolidine, pyrazolidine, morpholine, thiomorpholine, tetrahydrothiopyran,
`
`tetrahydrothiophene, and the like.
`
`"Aryl" refers to optionally substituted monocyclic and polycarbocyclic unfused or
`
`fused groups having 6 to 14 carbon atoms and having at least one aromatic ring that
`
`complies with HUckKel’s Rule. Examples of aryl groups are phenyl, biphenyl, naphthyl,
`
`anthracenyl, phenanthreny] and the like.
`
`"Heteroaromatic ring" means an optionally substituted aromatic monocyclic ring or
`
`10
`
`polycarbocyclic fused ring system wherein at least one ring complies with HUckel’s Rule,
`
`has the specified number of ring atoms, and that ring containsat least one heteratom
`
`selected from N, O, and/or S. Examples ofthese groups include furanyl, thiopheny],
`
`pytrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl,
`
`oxadiazolyl, oxo-pyridyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl,
`
`15
`
`pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indolyl, and
`
`indazolyl.
`
`"Enantiomerically enriched" refers to products whose enantiomeric excess is
`
`greater than zero. For example, enantiomerically enriched refers to products whose
`
`enantiomeric excess 1s greater than 50% ee, greater than 75% ee, and greater than 90% ee.
`
`20
`
`"Enantiomcric cxccss" or "cc" is the excess of one cnantiomer over the other
`
`expressed as a percentage. As aresult, since both enantiomers are present in equal
`
`amounts in aracemic mixture, the enantiomeric excess is zero (0% ee). However, if one
`
`enantiomer was enriched such that it constitutes 95% of the product, then the enantiomeric
`
`excess would be 90% ee (the amount of the enriched enantiomer, 95%, minus the amount
`
`25
`
`of the other enantiomer, 5%).
`
`"Enantiomerically pure" means products whose enantiomeric excess is 99% ee or
`
`greater.
`
`"Halo" means the halogen radical fluoro, chloro, bromo, or iodo.
`
`"Haloalkyl" means an alkyl group that is substituted with onc or morc halo
`
`30
`
`substituents. Haloalkyl includes trifluoromethyl] andtrifluoroethyl.
`
`Certain compounds of formula (D have a basic nitrogen group and are therefore
`
`capable of forming pharmaceutically-acceptable acid addition salts by treatment with a
`
`suitable acid. Suitable acids include pharmaceutically-acceptable inorganic acids amd
`
`6
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`pharmaceutically-acceptable organic acids. Representative pharmaceutically-acceptable
`
`acid addition salts include hydrochloride, hydrobromide, nitrate, methylnitrate, sulfate,
`
`bisulfate, sulfamate, phosphate., acetate, hydroxyacetate, phenylacetate, propionate,
`
`butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate,
`
`tartrate, citrate, salicylate, /?-aminosalicyclate, glycollate, lactate, heptanoate, phthalate,
`
`oxalate, succinate, benzoate, o-acetoxybenzoate, chlorobenzoate, methylbenzoate,
`
`dinitrobenzoate, hydroxybenzoate, methoxybenzoate, mandelate, tannate, formate,
`
`stearate, ascorbate, palmitate, oleate, pyruvate, pamoate, malonate, laurate, glutarate,
`
`glutamate, estolate, methanesulfonate (mesylate), ethanesulfonate (esylate), 2-
`
`10
`
`hydroxy ethanesulfonate, benzenesulfonate (besylate), /?-aminobenzenesulfonate,p -
`
`tolucncsulfonate (tosylate), and napthalcnc-2-sulfonate.
`
`Certain other compounds of formula (1) have an acidic functional group, one acidic
`
`enough to form salts. Representative salts include pharmaceutically-acceptable metal salts
`
`such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc salts;
`
`15
`
`carbonates and bicarbonates of a pharmaceutically-acceptable metal cation such as sodium,
`
`potassium, lithium, calcium, magnesium, aluminum, and zinc; pharmaceutically-
`
`acceptable organic primary, secondary, and tertiary amines including aliphatic amines,
`
`aromatic amines, aliphatic diamines, and hydroxy alkylamines such as methylamine,
`
`ethylamine, 2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine,
`
`20
`
`cthanolamine, dicthanolamine, and cyclohexylaminc.
`
`The compounds according to formula (I) may contain one or more asymmetric
`
`center, also referred to as a chiral center, and may, therefore, exist as individual
`
`enantiomers, diastereomers, or other stereoisomeric forms, or as mixtures thereof. Chiral
`
`centers may also be present in a substituent such as an alkyl group. Where the
`
`25
`
`stereochemistry of a chiral center present in formula I, or in any chemical structure
`
`illustrated herein, is not specified the structure is intended to encompass any stereoisomer
`
`and all mixtures thereof. Thus, compounds according to formula I containing one or more
`
`chiral center may be used as racemic mixtures, enantiomerically enriched mixtures, or as
`
`enantiomerically pure individual stereoisomers.
`
`30
`
`Individual stereoisomers of a compound according to formula I which contain one
`
`or more asymmetric center may be resolved by methods knownto those skilled in theart.
`
`For example, such resolution may be carried out (1) by formation of diastereoisomeric
`
`salts, complexes or other derivatives; (2) by selective mixture with a stereoisomer-specific
`
`7
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid
`
`chromatography in a chiral enviornment, for example, on a chiral support such assilica
`
`with a bound chiral ligand or in the presence of a chiral solvent. The skilled artisan will
`
`appreciate that where the desired stereoisomer is converted into another chemical entity by
`
`one of the separation procedures described above, a further step is required to liberate the
`
`desired form. Alternatively, specific stereoisomers may be synthesized by asymmetric
`
`synthesis using optically active reagents, substrates, catalysts or solvents, or by converting
`
`one enantiomerto the other by asymmetric transformation.
`
`The compoundsof the invention may exist in solid or liquid form.
`
`In the solid
`
`10
`
`state, the compoundsof the invention may exist in crystalline or noncrystalline form, or as
`
`a mixture thercof. For compoundsof the invention that are in crystalline form, the skilled
`
`artisan will appreciate that pharmaccutically-acceptable solvates may be formed wherein
`
`solvent molecules are incorporated into the crystalline lattice during crystallization.
`
`Solvates may involve nonaqueous solvents such as ethanol, isopropanol, DMSO,acetic
`
`15
`
`acid, ethanolamine, and ethyl acetate, or they may involve water as the solvent that is
`
`incorporated into the crystalline lattice. Solvates wherein water is the solvent that is
`
`incorporated into the crystalline lattice are typically referred to as "hydrates." Hydrates
`
`include stoichiometric hydrates as well as compositions containing vaiable amounts of
`
`water. The invention includes all such solvates.
`
`20
`
`The skilled artisan will further appreciate that ccrtain compoundsofthe invention
`
`that exist in crystalline form, including the various solvates thereof, may exhibit
`
`polymorphism, i.e. the capacity to occur in different crystalline structures. These different
`
`crystalline forms are typically known as polymorphs. The invention includes all such
`
`polymorphs. Polymorphs typically exhibit different melting points, IR spectra, and X-ray
`
`25
`
`powder diffraction patterns, which may be used for identification. The skilled artisan will
`
`appreciate that different polymorphs may be produced, for example, by changing or
`
`adjusting the mixture conditions or reagents, used in making the compound. For example,
`
`changes in temperature, pressure, or solvent may result in polymophs.
`
`In addition, one
`
`polymorph may spontaneously convert to another polymorph under certain conditions.
`
`30
`
`The compounds of the invention inhibit the cathepsin C enzyme and can be useful
`
`in the treatment of conditions wherein the underlying pathology is (at least in part)
`
`attributable to cathepsin C involvement or in conditions wherein cathepsin C inhibition
`
`offers some clinical benefit even though the underlying pathology is not (even in part)
`
`8
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`attributable to cathepsin C involvement. Examples of such conditions include COPD,
`
`rheumatoid arthritis, osteoarthritis, asthma, and multiple sclerosis. Accordingly, in another
`
`aspect the invention is directed to methods oftreating such conditions.
`
`The methods of treatment of the invention comprise administering a safe and
`
`effective amount of a compound of the invention to a patient in need thereof.
`
`As used herein, "treatment" in reference to a condition means: (1) the amelioration
`
`or prevention of the condition being treated or one or more of the biological manifestations
`
`of the condition being treated, (2) the interference with (a) one or more points in the
`
`biological cascade that leads to or is responsible for the condition being treated or (b) one
`
`10
`
`or more of the biological manifestations of the condition being treated, or (3) the
`
`alleviation of one or more of thc symptomsor cffccts associated with the condition being
`
`treated.
`
`As indicated above, "treatment" of a condition includes prevention of the
`
`condition. The skilled artisan will appreciate that "prevention" is not an absolute term.
`
`In
`
`15
`
`medicine, "prevention" is understood to refer to the prophylactic administration of a drug
`
`to substantially diminish the likelihood or severity of a condition or biological
`
`manifestation thereof, or to delay the onset of such condition or biological manifestation
`
`thereof.
`
`As used herein, "safe and effective amount" and "therapeutically effective amount”
`
`20
`
`in reference to a compound of formula I, or a pharmaccutically acccptable salt of it, mcans
`
`an amountof sufficicnt to significantly inducc a positive modification in the condition to
`
`be treated but low enoughto avoid serious side effects at a reasonable benefit/risk ratio
`
`within the scope of sound medical judgment. A safe and effective amount of a compound
`
`of the invention will vary with the particular compound chosen, e.g. consider the potency,
`
`25
`
`efficacy, and half-life of the compound; the route of administration chosen; the condition
`
`being treated; the severity of the condition being treated; the age, size, weight, and
`
`physical condition of the patient being treated; the medical history of the patient to be
`
`treated; the duration of the treatment; the nature of concurrent therapy; the desired
`
`therapcutic cffect; and like factors, but can nevertheless be routincly determined by the
`
`30
`
`skilled artisan.
`
`As used herein, "patient" refers to a human or animal.
`
`The compounds of the invention may be administered by any suitable route of
`
`administration, including both systemic administration and topical administration.
`
`9
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`Systemic administration includes oral administration, parenteral administration,
`
`transdermal administration, rectal administration, and administration by inhalation.
`
`Parcntcral administration rcfcrs to routes of administration othcr than enteral, transdcrmal,
`
`or by inhalation, and is typically by injection or infusion. Parenteral administration
`
`includes intravenous, intramuscular, and subcutaneous injection or infusion.
`
`Inhalation
`
`refers to administration into the patient's lungs whether inhaled through the mouth or
`
`through the nasal passages. Topical administration includes application to the skin as well
`
`as intraocular, otic, intravaginal, and intranasal administration.
`
`The compounds of the invention may be administered once or according to a
`
`10
`
`dosing regimen wherein a number of doses are administered at varying intervals of time
`
`for a given period of time. For cxamplc, doscs may be administcred one, two, three, or
`
`four times per day. Doses may be administered until the desired therapeutic effect is
`
`achieved or indefinitely to maintain the desired therapeutic effect. Suitable dosing
`
`regimens for a compound of the invention depend on the pharmacokinetic properties of
`
`15
`
`that compound, such as absorption, distribution, and half-life, which can be determined by
`
`the skilled artisan.
`
`In addition, suitable dosing regimens, including the amount
`
`administered and the duration such regimens are administered, for a compound ofthe
`
`invention depend on the condition being treated, the severity of the condition being treated,
`
`the age and physical condition of the patient being treated, the medical history of the
`
`20
`
`patient to be treated, the nature of concurrent therapy, the particular route of administration
`
`chosen, the desired therapeutic effect, and like factors within the knowledge and expertise
`
`of the skilled artisan.
`
`It will be further understood by suchskilled artisans that suitable
`
`dosing regimens may require adjustment given an individual patient's response to the
`
`dosing regimen or over time as individual patient needs change. Typical daily dosages
`
`25
`
`range from 10 mg to 1000 mg.
`
`Compositions
`
`The compounds of the invention will normally, but not necessarily, be formulated
`
`into a pharmaceutical composition prior to administration to a patient. Accordingly, in
`
`30
`
`another aspect the invention is directed to pharmaceutical compositions comprising a
`
`compound of the invention and a pharmaceutically-acceptable excipient.
`
`The pharmaceutical compositions of the invention may be prepared and packaged
`
`in bulk form wherein a safe and effective amount of a compound of the invention can be
`
`10
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`extracted and then given to the patient such as with powders, syrups, and solutions for
`
`injection. Alternatively, the pharmaceutical compositions of the invention may be
`
`prepared and packaged in unit dosage form wherein each physically discrete unit contains
`
`a safe and effective amount of a compound of the invention. When prepared in unit dosage
`
`form, the pharmaceutical compositions of the invention typically contain from 1 mg to
`
`1000 mg.
`
`The pharmaceutical compositions of the invention typically contain one compound
`
`of the invention. However, in certain embodiments, the pharmaceutical compositions of
`
`the invention contain more than one compound of the invention. For example, in certain
`
`10
`
`embodiments the pharmaceutical compositions of the invention contain two compounds of
`
`the invention. In addition, the pharmaceutical compositions of the invention may
`
`optionally further comprise onc or more additional pharmaccutically active compounds.
`
`Conversely, the pharmaceutical compositions of the invention typically contain more than
`
`one pharmaceutically-acceptable excipient. However, in certain embodiments, the
`
`15
`
`pharmaceutical compositions of the invention contain one pharmaceutically-acceptable
`
`excipient.
`
`As used herein, "pharmaceutically-acceptable excipient" means a material,
`
`composition or vehicle involved in giving form or consistency to the composition and
`
`which is safe when administered to a patient. Each excipient must be compatible with the
`
`20
`
`other ingredients of the pharmaceutical composition when commingled such that
`
`interactions which would substantially reduce the efficacy of the compound ofthe
`
`invention when administered to a patient and interactions which would result in
`
`pharmaceutical compositions that are not pharmaceutically acceptable are avoided.
`
`In
`
`addition, each excipient must of course be of sufficiently high purity to render it
`
`25
`
`pharmaceutically-acceptable.
`
`The compounds of the invention and the pharmaceutically-acceptable excepient or
`
`excepients will typically be formulated into a dosage form adapted for administration to
`
`the patient by the desired route of administration. For example, dosage forms include
`
`those adapted for (1) oral administration such as tablcts, capsules, caplcts, pills, troches,
`
`30
`
`powders, syrups, elixers, suspensions, solutions, emulsions, sachets, and cachets; (2)
`
`parenteral administration suchas sterile solutions, suspensions, and powders for
`
`reconstitution; (3) transdermal administration such as transdermal patches; (4) rectal
`
`administration such as suppositories; (5) inhalation such as aerosols and solutions; and (6)
`
`11
`
`

`

`WO 2009/129365
`
`PCT/US2009/040754
`
`topical administration such as creams, ointments, lotions, solutions, pastes, sprays, foams,
`
`and gels.
`
`Suitable pharmaceutically-acceptable excipients will vary depending upon the
`
`particular dosage form chosen.
`
`In addition, suitable pharmaceutically-acceptable
`
`excipients may be chosen for a particular function that they may serve in the composition.
`
`For example, certain pharmaceutically-acceptable excipients may be chosen for their
`
`ability to facilitate the production of uniform dosage forms. Certain pharmaceutically-
`
`acceptable excipients may be chosen fortheir ability to facilitate the production of stable
`
`dosage forms. Certain pharmaceutically-acceptable excipients may be chosen for their
`
`10
`
`ability to facilitate the carrying or transporting the compound or compoundsof the
`
`invention once administered to the patient from one organ, or portion of the body, to
`
`another organ, or portion of the body. Certain pharmaceutically-acceptable excipients may
`
`be chosen for their ability to enhance patient compliance.
`
`Suitable pharmaceutically-acceptable excipients include the following types of
`
`15
`
`excipients: Diluents, fillers, binders, disintegrants, lubricants, glidants, granulating agents,
`
`coating agents, wetting agents, solvents, co-solvents, suspending agents, emulsifiers,
`
`sweetners, flavoring agents, flavor masking agents, coloring agents, anticaking agents,
`
`hemectants, chelating agents, plasticizers, viscosity increasing agents, antioxidants,
`
`preservatives, stabilizers, surfactants, and buffering agents. The skilled artisan will
`
`20
`
`appreciate that certain pharmaceutically-acceptable excipients may serve more than one
`
`function and may serve alternative functions depending on how much of the excipient is
`
`present in the formulation and what ot

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

PTO Denying Access

Refresh this Document
Go to the Docket